Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026)
Aclaris Therapeutics' quarterly Profit After Tax came in at -$19.8 million in Q1 2026, down 31.42% year-on-year from -$28.9 million in Q1 2025, and little changed quarter-over-quarter from -$19.8 million in Q4 2025.
Aclaris Therapeutics has reported Profit After Tax for 13 years, with the latest figure at -$19.8 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 31.42% year-over-year to -$19.8 million; the trailing twelve-month figure through Mar 2026 stood at -$69.7 million (up 46.5% YoY), and the FY2025 full-year result was -$64.9 million, up 50.84% from the prior year.
- Profit After Tax for Q1 2026 stood at -$19.8 million, roughly flat from -$19.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$1.5 million in Q4 2023, with the low at -$96.6 million in Q4 2024.
- Average Profit After Tax over 5 years is -$23.1 million, with a median of -$19.8 million recorded in 2025.
- Year-over-year, Profit After Tax jumped 94.6% in 2023 and sank 6375.65% in 2024.
- Tracing ACRS's Profit After Tax over 5 years: stood at -$27.6 million in 2022, then jumped by 94.6% to -$1.5 million in 2023, then slumped by 6375.65% to -$96.6 million in 2024, then soared by 79.5% to -$19.8 million in 2025, then slipped by 0.15% to -$19.8 million in 2026.
- The last three Profit After Tax figures came in at -$19.8 million (Q1 2026), -$19.8 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Aclaris Therapeutics | 586.09 Mn | 586.09 Mn | 1.60 Mn | -19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.82 Mn |
| Dec 31, 2025 | -19.80 Mn |
| Sep 30, 2025 | -14.61 Mn |
| Jun 30, 2025 | -15.43 Mn |
| Mar 31, 2025 | -15.09 Mn |
| Dec 31, 2024 | -96.55 Mn |
| Sep 30, 2024 | -7.59 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -16.94 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | -29.26 Mn |
| Jun 30, 2023 | -29.57 Mn |
| Mar 31, 2023 | -28.16 Mn |
| Dec 31, 2022 | -27.64 Mn |
| Sep 30, 2022 | -19.95 Mn |
| Jun 30, 2022 | -20.53 Mn |
| Mar 31, 2022 | -18.79 Mn |
| Dec 31, 2021 | -22.80 Mn |
| Sep 30, 2021 | -21.15 Mn |
| Jun 30, 2021 | -18.16 Mn |
| Mar 31, 2021 | -28.75 Mn |
| Dec 31, 2020 | -13.17 Mn |
| Sep 30, 2020 | -10.66 Mn |
| Jun 30, 2020 | -11.60 Mn |
| Mar 31, 2020 | -15.59 Mn |
| Dec 31, 2019 | -19.45 Mn |
| Sep 30, 2019 | -23.14 Mn |
| Jun 30, 2019 | -49.88 Mn |
| Mar 31, 2019 | -37.57 Mn |
| Dec 31, 2018 | -38.55 Mn |
| Sep 30, 2018 | -20.63 Mn |
| Jun 30, 2018 | -31.22 Mn |
| Mar 31, 2018 | -30.23 Mn |
| Dec 31, 2017 | -22.93 Mn |
| Sep 30, 2017 | -18.19 Mn |
| Jun 30, 2017 | -14.84 Mn |
| Mar 31, 2017 | -12.56 Mn |
| Dec 31, 2016 | -11.48 Mn |
| Sep 30, 2016 | -10.69 Mn |
| Jun 30, 2016 | -12.87 Mn |
| Mar 31, 2016 | -13.04 Mn |
| Dec 31, 2015 | -4.71 Mn |
| Sep 30, 2015 | -10.63 Mn |
| Jun 30, 2015 | -2.59 Mn |
| Mar 31, 2015 | -2.62 Mn |
| Dec 31, 2014 | -2.60 Mn |
| Sep 30, 2014 | -2.66 Mn |